Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CCO Independent Conference Highlights of the Virtual 2021 Gastrointestinal (GI) Cancers Symposium

Axel Grothey Headshot
Axel Grothey, MD
Manish A. Shah, MD
Released: March 10, 2021
Back Next

References

  1. André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383:2207-2218.
  2. Shiu K-K, Andre T, Won Kim T, et al. KEYNOTE-177: phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 6.
  3. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) vs standard therapy in participants with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (MK-3475-177/KEYNOTE-177). Available at: https://clinicaltrials.gov/ct2/show/NCT02563002. Accessed February 22, 2021.
  4. Van Cutsem E, Danielewicz I, Saunders MP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol. 2020;31:1160-1168.
  5. Van Cutsem E, Danielewicz I, Saunders MP, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): results of the final analysis on the overall survival. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 14.
  6. ClinicalTrials.gov. A study evaluating S 95005 plus bevacizumab and capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapy (TASCO1). Available at: https://clinicaltrials.gov/ct2/show/NCT02743221. Accessed February 22, 2021.
  7. Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412-420.
  8. ClinicalTrials.gov. Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE). Available at: https://clinicaltrials.gov/ct2/show/NCT03869892. Accessed February 22, 2021.
  9. Loree JM, Topham JT, Kennecke HF, et al. Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC). Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 61.
  10. ClinicalTrials.gov. Durvalumab and tremelimumab and best supportive care vs best supportive care in patients with advanced colorectal cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02870920. Accessed February 22, 2021.
  11. Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncol. 2020;6:831-838.
  12. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353-1365.
  13. Osumi H, Shinozaki E, Yamaguchi K, et al. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci Rep. 2019;9:17358.
  14. Henriksen TV, Tarazona N, Reinert T, et al. Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 11.
  15. ClinicalTrials.gov. Circulating tumor DNA testing in predicting treatment for patients with stage IIA colon cancer after surgery. Available at: https://clinicaltrials.gov/ct2/show/NCT04068103. Accessed February 22, 2021.
  16. ANZCTR.org.au. Circulating tumour DNA (ctDNA) analysis informing adjuvant chemotherapy in stage II colon cancer. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000381583. Accessed February 22, 2021.
  17. ClinicalTrials.gov. Veliparib, pembrolizumab, and combination chemotherapy in treating patient with locally advanced rectal cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02921256. Accessed February 22, 2021.
  18. Rahma OE, Yothers G, Hong TS, et al. NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—pembrolizumab experimental arm (EA) primary results. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 8.
  19. ClinicalTrials.gov. PROSPECT: chemotherapy alone or chemotherapy plus radiation therapy in treating patients with locally advanced rectal cancer undergoing surgery. Available at: https://clinicaltrials.gov/ct2/show/NCT01515787. Accessed February 22, 2021.
  20. ClinicalTrials.gov. Non-operative management for locally advanced rectal cancer (NOM). Available at: https://clinicaltrials.gov/ct2/show/NCT03179540. Accessed February 22, 2021.
  21. Wainberg ZA, Enzinger PC, Kang Y-K, et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 160.
  22. ClinicalTrials.gov. A study of bemarituzumab (FPA144) combined with modified FOLFOX6 (mFOLFOX6) in gastric/gastroesophageal junction cancer (FIGHT). Available at: https://clinicaltrials.gov/ct2/show/NCT03694522. Accessed February 22, 2021.
  23. Catenacci DV, Tesfaye A, Tejani M, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019;15:2073-2082.
  24. Chen L-T, Satoh T, Ryu M-H, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510-519.
  25. ClinicalTrials.gov. Study of ONO-4538 in unresectable advanced or recurrent gastric cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02267343. Accessed February 22, 2021.
  26. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Program and abstracts of the 2020 European Society for Medical Oncology Virtual Congress; September 19-21, 2020. Abstract LBA6_PR.
  27. ClinicalTrials.gov. Efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer (CheckMate649). Available at: https://clinicaltrials.gov/ct2/show/NCT02872116. Accessed February 22, 2021.
  28. Strickler JH, Nakamura Y, Yoshino T, et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract TPS252.
  29. Strickler JH, Ng K, Cercek A, et al. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract TPS153.
  30. Janjigian YY, Viglianti N, Liu F, Mendoza-Naranjo A, Croydon L. A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03). Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract TPS261.
  31. Raghav KPS, Yoshino T, Taniguchi H, et al. An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract TPS157.
  32. Shah MA, Ajani JA, Al-Batran S-E, et al. Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. Program and abstracts of the 2020 ASCO Annual Meeting; May 29-31, 2020. Abstract TPS4648.
  33. ClinicalTrials.gov. A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (GLOW). Available at: https://clinicaltrials.gov/ct2/show/NCT03653507. Accessed February 22, 2021.
  34. ClinicalTrials.gov. Efficacy and safety of pembrolizumab (MK-3475) plus lenvatinib (E7080/MK-7902) in previously treated participants with select solid tumors (MK-7902-005/E7080-G000-224/LEAP-005). Available at: https://clinicaltrials.gov/ct2/show/NCT03797326. Accessed February 22, 2021.
  35. Chung HC, Lwin Z, Gomez-Roca C, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the gastric cancer cohort. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 230.
  36. Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1057-1065.
  37. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.
  38. Shitara K, Özgüro─člu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123-133.
  39. Lwin Z, Gomez-Roca C, Saada-Bouzid E, et al. LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Ann Oncol. 2020;31(suppl4):S1142-S1215.
  40. Gomez-Roca C, Yanez E, Im SA, et al. LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 94.
  41. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437-1448.
  42. Tabernero J, Shitara K, Zaanan A, et al. Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 229.
  43. ClinicalTrials.gov. Study of TAS-102 or placebo plus BSC in patients with metastatic gastric cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02500043. Accessed February 22, 2021.
  44. Shitara K, George B, Taieb J, et al. The impact of prior therapies on outcomes with trifluridine/tipiracil (FTD/TPI) in the phase III TAGS trial. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 247.
  45. Ghidini M, Hochester HS, Doi T, et al. Body weight loss (BWL) as a prognostic/predictive factor in previously treated patients (pts) with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC): Post-hoc analyses of the phase III tags trial. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 476.
  46. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 377.
  47. ClinicalTrials.gov. Combination chemotherapy with or without hypofractionated radiation therapy before surgery in treating patients with pancreatic cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02839343. Accessed February 22, 2021.
  48. Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 378.
  49. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
  50. ClinicalTrials.gov. Olaparib in gBRCA mutated pancreatic cancer whose disease has not progressed on first line platinum-based chemotherapy (POLO). Available at: https://clinicaltrials.gov/ct2/show/NCT02184195. Accessed February 22, 2021.
  51. Olaparib [package insert]. Wilmington, DE. AstraZeneca Pharmaceuticals LP; 2020.
  52. Van Laethem J-L, Borbath I, Karwal M, et al. Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 297.
  53. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) as monotherapy in participants with advanced hepatocellular carcinoma (MK-3475-224/KEYNOTE-224). Available at: https://www.clinicaltrials.gov/ct2/show/NCT02702414. Accessed February 22, 2021.
  54. Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 265.
  55. ClinicalTrials.gov. A phase II, single arm study of BGJ398 in patients with advanced cholangiocarcinoma. Available at: https://clinicaltrials.gov/ct2/show/NCT02150967. Accessed February 22, 2021.
  56. Zhu AX, Macarulla T, Javle MM, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. Program and abstracts of the 2021 ASCO GI Cancers Symposium; January 15-17, 2021. Abstract 266.
  57. ClinicalTrials.gov. Study of AG-120 in previously treated advanced cholangiocarcinoma with IDH1 Mutations (ClarIDHy). Available at: https://clinicaltrials.gov/ct2/show/NCT02989857. Accessed February 22, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.
Seagen Inc.
Taiho Oncology Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings